Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20854970 | 0.85 | AOC3 (0.35) | CA2 | |
| SCHEMBL14873994 | 0.85 | ATM (0.37) | CYP2C19ALOX15L3MBTL1MEN1KMT2A | |
| SCHEMBL20640547 | 0.84 | CA2 (0.34) | ALDH1A1MAPTRIPK1L3MBTL1KMT2A | |
| SCHEMBL13189966 | 0.83 | CYP2C19 (0.43) | CYP2C19ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL933402 | 0.83 | APLNR (0.36) | MEN1KMT2ACA2 | |
| SCHEMBL407311 | 0.82 | ATM (0.32) | CYP2C19ALDH1A1MAPTKDM4ERIPK1 | |
| SCHEMBL5965537 | 0.81 | CYP19A1 (0.32) | CYP2C19ALOX5 | |
| SCHEMBL6435514 | 0.81 | CYP2C19 (0.41) | CYP2C19ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL20645830 | 0.80 | IDO1 (0.38) | SMN1; SMN2 | |
| SCHEMBL30955354 | 0.80 | IDO1 (0.38) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119613408-A | Bicyclic ketone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-110914271-B | Bicyclic ketone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240300974-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| CN-111201229-B | Bicyclic compounds useful as inhibitors of RIP1 kinase | 豪夫迈·罗氏有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-112074519-B | Compounds useful as inhibitors of RIP1 kinase for the treatment of, for example, irritable Bowel Syndrome (IBS) | 豪夫迈·罗氏有限公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-4397309-A2 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-3781571-B1 | N-[4-OXO-2,3-DIHYDRO-PYRIDO[3,2-B][1,4]OXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOLE-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS) | HOFFMANN LA ROCHE (CH) | 2024-01-17 | — | — | EP | disclosed |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20200283446-A1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| CN-111201229-A | Bicyclic compounds useful as RIP1 kinase inhibitors | 豪夫迈·罗氏有限公司 | 2020-05-26 | — | — | CN | disclosed |
| CN-110914271-A | Bicyclic ketone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2019012063-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2019-01-17 | — | — | WO | disclosed |
| US-8263774-B2 | Quinoline-oxazoline compounds and their use in oxidation synthesis | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263774-B2 | Quinoline-oxazoline compounds and their use in oxidation synthesis | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110054176-A1 | QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
| US-20110054176-A1 | QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054176-A1 | QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS | XDH, OXA1L, AOX1 | CYP2C19 152/4885ALDH1A1 421/4885SMN1; SMN2 2877/4885 |
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | CYP2C19 45/4885ALDH1A1 184/4885SMN1; SMN2 3876/4885 |
| US-20200283446-A1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | CYP2C19 4501/4885ALDH1A1 3998/4885SMN1; SMN2 3019/4885 |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | HSD17B7, CYP11B1, CYP11B2 | CYP2C19 45/4885ALDH1A1 184/4885SMN1; SMN2 3876/4885 |
| US-20240300974-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | CYP2C19 45/4885ALDH1A1 184/4885SMN1; SMN2 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.